Skip to main content

Table 2 Physical characterization data for the transdermal patches

From: Formulation and characterization of transdermal patches for controlled delivery of duloxetine hydrochloride

Formulation code

Weighta(mg) ± SD

Thicknessa(mm) ± SD

Foldingaendurance ± SD

Diametera(cm) ± SD

Area (cm2)

Flatness (%)

Surface pH

A1

207.30 ± 2.68

0.053 ± 0.001

306.3 ± 2.52

4.03 ± 0.03

12.56

100

5.43

A2

168.10 ± 3.64

0.050 ± 0.002

302.0 ± 1.73

4.06 ± 0.02

12.87

100

5.48

A3

201.10 ± 2.48

0.048 ± 0.001

304.6 ± 2.51

4.10 ± 0.05

13.51

100

5.66

A4

160.70 ± 2.32

0.047 ± 0.001

300.0 ± 1.73

4.03 ± 0.02

12.87

100

5.56

B1

240.80 ± 2.74

0.054 ± 0.001

308.6 ± 2.08

4.06 ± 0.02

13.19

100

5.71

B2

184.00 ± 2.16

0.048 ± 0.001

308.0 ± 2.64

4.06 ± 0.02

12.87

100

5.74

B3

178.70 ± 1.34

0.050 ± 0.002

306.6 ± 2.08

4.08 ± 0.02

12.87

100

5.63

B4

161.80 ± 2.21

0.050 ± 0.001

303.3 ± 1.53

4.05 ± 0.04

12.87

100

5.67

C1

209.70 ± 4.01

0.049 ± 0.001

301.1 ± 2.31

4.11 ± 0.02

13.51

100

5.47

C2

203.70 ± 3.77

0.052 ± 0.001

298.0 ± 2.64

4.06 ± 0.02

13.19

100

5.47

C3

245.90 ± 2.45

0.053 ± 0.002

302.6 ± 2.08

4.06 ± 0.02

12.87

100

5.67

C4

207.10 ± 2.77

0.050 ± 0.001

298.3 ± 2.08

4.06 ± 0.03

13.19

100

5.52

  1. aCalculated as mean of measurements in triplicate